Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™ platform, announced the closing of its oversubscribed seed financing round, raising $4.3 million against a $4 million target.

The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research and the Asian Fund for Cancer Research, Bootstrap Ventures, and institutional investors, impact funds, and healthcare executives.

Acurion is a precision oncology company developing AI-powered image analysis tools for biomarker detection, uncovering clinically actionable insights from conventional pathology images. Unlike genomic testing approaches often requiring additional tissue or specialized molecular testing, Acurion's OncoGaze™ platform extracts biomarker insights from routine pathology slides prepared during standard clinical care, enabling an instantaneous, scalable and accessible approach to precision medicine.

Despite major advances in targeted therapies, many cancer patients either lack access to biomarker testing or face life-threatening testing delays. Acurion aims to expand access to precision oncology by improving biomarker detection and treatment selection across multiple advanced cancer types.